company background image
4588 logo

Oncolys BioPharma TSE:4588 Stock Report

Last Price

JP¥656.00

Market Cap

JP¥16.3b

7D

-1.5%

1Y

16.7%

Updated

13 Dec, 2024

Data

Company Financials

4588 Stock Overview

Engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. More details

4588 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Oncolys BioPharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oncolys BioPharma
Historical stock prices
Current Share PriceJP¥656.00
52 Week HighJP¥918.00
52 Week LowJP¥420.00
Beta0.61
1 Month Change-20.00%
3 Month Change14.49%
1 Year Change16.73%
3 Year Change6.15%
5 Year Change-66.27%
Change since IPO-81.42%

Recent News & Updates

Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Jun 17
Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Recent updates

Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Jun 17
Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

Feb 29
Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

Shareholder Returns

4588JP BiotechsJP Market
7D-1.5%-1.1%0.7%
1Y16.7%22.8%15.5%

Return vs Industry: 4588 underperformed the JP Biotechs industry which returned 22.7% over the past year.

Return vs Market: 4588 matched the JP Market which returned 17.1% over the past year.

Price Volatility

Is 4588's price volatile compared to industry and market?
4588 volatility
4588 Average Weekly Movement10.2%
Biotechs Industry Average Movement7.1%
Market Average Movement3.6%
10% most volatile stocks in JP Market7.3%
10% least volatile stocks in JP Market1.9%

Stable Share Price: 4588's share price has been volatile over the past 3 months compared to the JP market.

Volatility Over Time: 4588's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
200438Yasuo Uratawww.oncolys.com

Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company’s product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use.

Oncolys BioPharma Inc. Fundamentals Summary

How do Oncolys BioPharma's earnings and revenue compare to its market cap?
4588 fundamental statistics
Market capJP¥16.28b
Earnings (TTM)-JP¥1.91b
Revenue (TTM)JP¥31.38m

518.9x

P/S Ratio

-8.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4588 income statement (TTM)
RevenueJP¥31.38m
Cost of RevenueJP¥0
Gross ProfitJP¥31.38m
Other ExpensesJP¥1.94b
Earnings-JP¥1.91b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 07, 2025

Earnings per share (EPS)-77.04
Gross Margin100.00%
Net Profit Margin-6,093.40%
Debt/Equity Ratio15.9%

How did 4588 perform over the long term?

See historical performance and comparison